低肾素性高血压:一种可基于机制治疗的独特表型
综述通过针对性文献检索,总结低肾素性高血压的流行病学、机制、诊断挑战与治疗。低肾素性高血压涵盖原发性醛固酮增多症、类似盐皮质激素过多的状态及肾小管钠转运障碍,患者对靶向钠潴留的治疗(盐皮质激素受体拮抗剂、上皮钠通道抑制剂或噻嗪类利尿剂)反应优于主要针对血管收缩的药物。
要点
- 低肾素性高血压是常见且具临床重要性的高血压表型。
- 扩大原发性醛固酮增多症筛查发现许多肾素受抑制但不符合醛固酮过量诊断标准者。
- 靶向钠潴留的治疗反应优于主要针对血管收缩的药物。
核心结论
- 低肾素性高血压是一种独特表型,识别后可实现基于机制的治疗,可能改善血压控制、减少用药负担并减轻长期心血管风险。
研究设计与样本
- 综述,通过针对性文献检索综合低肾素性高血压的流行病学、机制、诊断挑战与治疗证据。
主要发现
- 早期研究提出高血压时肾素可作为钠潴留和容量扩张的标志,提示肾素可指导个体化治疗。
- 肾素指导治疗策略历史上受限于检测变异性和高剂量盐皮质激素受体拮抗剂不良反应的担忧。
- 肾素检测性能改善、可及性增加及低剂量且耐受性更好的盐皮质激素受体拮抗剂可用,重新激发了对该策略的兴趣。
- 低肾素性高血压涵盖原发性醛固酮增多症、类似盐皮质激素过多的状态及肾小管钠转运障碍。
- 患者对盐皮质激素受体拮抗剂、上皮钠通道抑制剂或噻嗪类利尿剂反应优于主要针对血管收缩的药物。
临床怎么用
- 识别低肾素性高血压表型,优先选用靶向钠潴留的治疗(盐皮质激素受体拮抗剂、上皮钠通道抑制剂或噻嗪类利尿剂)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Low-renin hypertension is increasingly recognized as a common and clinically important form of hypertension. Expanded screening for primary aldosteronism has revealed many individuals with suppressed renin who do not meet the diagnostic criteria for aldosterone excess, yet exhibit features consistent with sodium retention or increased mineralocorticoid activity. This review synthesizes evidence from targeted literature searches on the epidemiology, mechanisms, diagnostic challenges, and treatment of low-renin hypertension. Early studies proposed renin, in the presence of hypertension, as a marker of excess sodium retention and volume expansion, suggesting that renin could guide individualized therapy. Adoption of a renin-guided treatment approach was historically limited by assay variability and concerns regarding adverse effects from high-dose mineralocorticoid receptor antagonists. However, improvements in renin assay performance, increased accessibility and use of renin testing, and the availability of lower-dose and better-tolerated mineralocorticoid receptor antagonists have renewed interest in this strategy. Low-renin hypertension encompasses primary aldosteronism, conditions that mimic mineralocorticoid excess, and disorders of renal tubular sodium transport. Across this spectrum, patients respond more favorably to therapies targeting sodium retention: mineralocorticoid receptor antagonists, epithelial sodium channel inhibitors, or thiazide diuretics, than to agents directed primarily at vasoconstriction. Recognition of low-renin hypertension as a distinct phenotype enables mechanism-based therapy and may improve blood pressure control, reduce medication burden, and mitigate long-term cardiovascular risk.
引用
- Shah SS, Fuller PJ, Young MJ, et al. Low-renin hypertension: a distinct phenotype enabling mechanism-based treatment. J Clin Endocrinol Metab. 2026. PMID: 42504137. doi:10.1210/clinem/dgag292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。